Related Experiment Video

Updated: Jun 2, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR

Pierre Zindy1, Yann Bergé, Ben Allal

  • 1INSERM U563, Université Paul Sabatier, Toulouse, France.

Cancer Research
|April 19, 2011
PubMed

Insights

Cancer cells

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Therapeutic resistance to HER receptor antagonists is a significant clinical challenge.
  • Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway is implicated in resistance.
  • mTOR-dependent phosphorylation of 4E-BP1 affects translation initiation complex formation.

Purpose of the Study:

  • To investigate the role of the eukaryotic initiation factor 4F (eIF4F) complex in cancer cell response to HER receptor antagonists.
  • To determine if eIF4E expression influences sensitivity or resistance to targeted therapies.

Main Methods:

  • Treatment of breast, colon, and head and neck cancer cells with trastuzumab, cetuximab, and erlotinib.
  • Assessment of eIF4F complex formation.
  • Ectopic expression of eIF4E in cancer cells.
  • Evaluation of cell proliferation and xenograft tumor growth.
  • Analysis of eIF4E levels in patient tumor specimens.

Main Results:

  • Trastuzumab, cetuximab, and erlotinib decreased eIF4F complex formation in respective cancer cell lines.
  • Ectopic eIF4E expression restored eIF4F formation and conferred resistance to trastuzumab.
  • Overexpression of eIF4E rescued breast cancer xenografts from trastuzumab inhibition.
  • Higher eIF4E levels in breast tumors correlated with better response to trastuzumab-based therapy.

Conclusions:

  • eIF4F complex formation is a key mediator of response to HER2 and EGFR-targeting drugs.
  • eIF4E plays a critical role in mediating resistance to HER receptor antagonists.
  • eIF4E expression level may serve as a predictive biomarker for targeted cancer therapy response.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...